Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

Status:	Recruiting
Conditions:	Peripheral Vascular Disease, Cardiology
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - 80
Updated:	7/16/2013
Start Date:	January 2003
Contact:	Tanuj K Kamineni
Email:	tkamine@emory.edu
Phone:	404 712 0168

AIR STUDY

TITLE: Anti-Ischemic effects of Abciximab(Reopro)

PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small
stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable
statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).

INTERVENTION: Heparin vs. heparin + abciximab during PCI

PURPOSE: Measure the effects of abciximab on special healing blood stem cells
(EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on
microvascular blood flow.

PATIENT ASSESSMENT:

1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.

2. Measurement of blood flow in selected suitable patients

3. 10 minute questionnaire before discharge and on visit on day 28.

Inclusion Criteria:

1. Have either:

- clinical history of anginal symptoms or positive stress test or

- in stent restenosis

2. Have an angiographic >70% coronary artery stenosis that will be treated with coronary
angioplasty or stenting procedure

3. For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase
inhibitor or a stable statin dose

4. negative pregnancy test

5. are able to give informed consent

Exclusion Criteria:

1. Coronary intervention within four weeks prior to enrollment.

2. Treatment with abciximab antagonistwithin four weeks.

3. treatment with thrombolytic therapy within 48 hours

4. MI within 2 months.

5. recent infections

6. general anesthesia within 3 months.

7. renal failure

We found this trial at

sites

Emory University Hospital

1364 Clifton Rd NE
Atlanta, Georgia 30322

(404) 712-2000